People want intelligence from their biology. They will not hand over the raw biology to get it. VitaCrypt resolves that bargain.
We unify genetics, wearables, microbiome, environment and live science into one profile that is encrypted on the device and analyzed under fully homomorphic encryption, so the server computes without ever seeing the plaintext. FHE became practical for consumer apps only in the last eighteen months. We are building the product on top of it.
Consumer health and longevity is one of the fastest-moving categories in tech, and it runs on the most sensitive data a person owns. Every current player asks the user to trust them with raw genetics, labs and biometrics in plaintext. The 23andMe collapse showed what that trust is worth. VitaCrypt makes "we analyze it without ever seeing it" a literal, cryptographic claim rather than a privacy-policy promise.
Consumers already pay for biomarker testing, wearables and personalized protocols. The behavior exists; the privacy model is what's broken.
Breaches, data sales and bankruptcies have taught the market that "encrypted at rest" is not privacy. Buyers now ask a sharper question: who can actually see my data?
FHE moved from research to shipping client SDKs across 2024 and 2025. The technical risk that blocked this product for a decade just cleared.
This company was not buildable in 2022. Regulation, capital and the underlying cryptography all crossed the line that makes an encrypted consumer-health product both something the market now wants and something a small team can actually ship.
The competitive heat is real: Function Health sued Superpower in 2025 over advertising, a sign of how contested this category has become. We do not compete on drawing blood. We compete on the layer above it: privacy, unification and live-cited reasoning that no plaintext-holding competitor can match.
Any one of these is a feature. Together they are hard to copy: a competitor holding plaintext cannot bolt real privacy on after the fact, and a privacy-first newcomer still has to build the data fabric and the live-science engine from scratch.
The cryptography is not aspirational. Zama's published encrypted-DNA benchmark (bounty #95, 2024) hit 96% accuracy on encrypted ancestry classification in about five minutes, with the query genome encrypted and the reference panel in clear. That is the proof the core primitive works at usable latency. We are targeting the Zama Concrete ML / TFHE stack.
The full four-pillar deep dive → Cryptography and threat model →
No revenue, no users, no inflated metrics. At this stage the meaningful signal is technical de-risking and a credible path to a working product, not a hockey-stick chart. This is what exists today.
| Signal | What it shows | Status |
|---|---|---|
| Technical litepaper | Cryptography, threat model, integration and validation plan, written and published | Publishedread it now |
| FHE feasibility | Zama's 96% encrypted-DNA benchmark proves the core primitive works at usable latency | Validated externallybounty #95 |
| Integration path | Terra API collapses 20+ wearable integrations into one; the free-science corpus is mapped | Designedspec complete |
| Scientific rigor | NIH-validated PROMIS short-forms for subjective inputs, which no consumer competitor uses | Planned for MVP |
| Demand signal | Public waitlist open across investor, user, partner and press audiences | Collecting |
| First design partners | Targeted onboarding of the first cohort | Q4 2026 |
Pre-MVP. No production health data yet. Every status above is deliberately conservative.
VitaCrypt is founder-led and deliberately capital-efficient: the MVP is being built by one technical founder, which keeps burn near zero while the hardest technical risk gets retired first. That is the design of this stage, not a gap to apologize for. The raise turns a working MVP into a team.
Owns the encrypted compute pipeline on the Zama Concrete ML / TFHE stack and the client-side key handling.
Builds the on-device unification fabric and the source integrations: Terra for wearables, plus genetics, microbiome and lab uploads.
Owns the live-science engine and recommendation quality: the corpus, the retrieval, and the evidence grading.
The roles are named because the plan is specific. The bet an early investor makes here is on a founder who knows exactly what the money buys, and in what order.
This is an early, founder-led round. Its shape is intentionally flexible at this stage; the goal is the right partner, not a fixed term sheet on a public page. Round size, structure and the financial model live in the deck, shared on request.
Request the deck and data room, or email [email protected] directly. We respond within 48 hours.